LifeMD Plunges 24.16% as Revenue Misses Estimates

On August 6, 2025, LifeMD's stock experienced a significant drop of 24.16% in pre-market trading, reflecting investor concerns over the company's recent financial performance and future outlook.

LifeMD reported a 23% year-over-year increase in total revenue for the second quarter of 2025, reaching $62.2 million. However, this figure fell short of analyst estimates by approximately $4.1 million. The company's adjusted EBITDA also saw a substantial rise of 223%, reaching $7.1 million. Despite these positive developments, the telehealth provider's revenue growth was not enough to meet market expectations, leading to a decline in investor confidence.

In addition to missing revenue estimates, LifeMD also cut its full-year 2025 revenue guidance to a range of $250 million to $255 million, down from the previous estimate of $270.32 million. The company also reduced its adjusted EBITDA outlook for the year to $27 million to $29 million, from the prior range of $31 million to $33 million. These adjustments further contributed to the negative sentiment surrounding the stock, as investors reassessed the company's growth prospects and financial health.